MENS
Jyong Biotech Ltd. Ordinary Shares
There isn't enough reported data to score MENS yet.
MENS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
MENS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
MENS PE Valuation
MENS has no meaningful PE right now: it lost money over the past year.
MENS Forward outlook
There aren't enough analyst estimates for MENS to show an outlook.
MENS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.06 | -$0.02 |
MENS Quarterly Revenue
MENS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$426 | +$228 |
MENS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +101918% | +72.9M shares |
| 1 year | +101918% | +72.9M shares |
MENS has 73M diluted shares, up 101918% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
MENS Net Leverage
MENS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MENS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.7 | Neutral |
| Stochastic | 29.2 | Neutral |
MENS's weekly RSI is 36 (neutral) and its Stochastic is 29 (neutral).
MENS PE vs Healthcare Sector
MENS has no meaningful PE right now: it lost money over the past year.
MENS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.91 | 12% below |
| 20 week MA | $2.08 | 19% below |
| 50 week MA | $3.21 | 48% below |
MENS is in a downtrend: it's below all three of its weekly moving averages, and 48% below its 50-week average.
MENS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $8.01 | $3.22 | -60% |
| 2026 YTD | $3.22 | $1.68 | -48% |
MENS has finished every year since 2025 lower, and it's down 48% so far in 2026.